文献速递糖尿病

实时连续血糖监测在2型糖尿病合并终末期肾病血液透析患者中的随机对照试验

Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究为前瞻性随机交叉试验,比较实时连续血糖监测(rtCGM)与毛细血管血糖(CBG)检测在2型糖尿病合并终末期肾病血液透析成人患者中的效果。主要结局低血糖时间百分比(%TBR<70 mg/dL)两组无显著差异,但rtCGM组目标范围内时间(%TIR)更高、平均血糖更低、高于范围时间(%TAR)更少。

要点

  • rtCGM未显著改变TBR<70 mg/dL,低血糖时间总体较少。
  • rtCGM组TIR(63.4%)高于CBG组(54.5%),平均血糖更低。
  • rtCGM组TAR>180 mg/dL和>250 mg/dL均低于CBG组。

核心结论

  • 在2型糖尿病合并终末期肾病血液透析成人中,TBR较低且不受rtCGM使用影响。
  • 与CBG检测相比,rtCGM干预期间TIR和TAR改善。

研究设计与样本

  • 前瞻性、随机、交叉试验,比较rtCGM与毛细血管血糖检测在2型糖尿病合并终末期肾病血液透析成人中的效果。

主要发现

  • %TBR<70 mg/dL两组无显著差异(均值1.17%±1.8 vs. 1.29%±2.7;P=0.28)。
  • rtCGM干预后%TIR更高(63.4%±24 vs. 54.5%±23),平均血糖更低(173.6±37 vs. 187.7±38 mg/dL)。
  • %TAR>180 mg/dL(35.3%±25 vs. 44.3%±23)和>250 mg/dL(12.3%±15 vs. 18.8%±19)均下降(所有P≤0.01)。

临床怎么用

  • 对于2型糖尿病合并终末期肾病血液透析患者,rtCGM可改善血糖控制指标(TIR、TAR),且不增加低血糖时间。
  • 需未来研究进一步确认rtCGM在该人群中的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is a need for improved glycemia monitoring tools for people with type 2 diabetes (T2D) and end-stage kidney failure (ESKF). RESEARCH DESIGN AND METHODS: This prospective, randomized, crossover trial compared the efficacy of real-time continuous glucose monitoring (rtCGM) with capillary blood glucose (CBG) testing in adults with T2D and ESKF undergoing hemodialysis. The primary outcome was percentage of time below range (%TBR) <70 mg/dL. RESULTS: The %TBR <70 mg/dL was not significantly different between groups (mean 1.17% ± 1.8 vs. 1.29% ± 2.7; P = 0.28). Compared with CBG testing, percentage time in range (%TIR) was higher (63.4% ± 24 vs. 54.5% ± 23) and mean glucose lower (173.6 ± 37 vs. 187.7 ± 38 mg/dL) after the rtCGM intervention, while percentage time above range (%TAR) >180 mg/dL (35.3% ± 25 vs. 44.3% ± 23) and >250 mg/dL decreased (12.3% ± 15 vs. 18.8% ± 19) (all P ≤ 0.01). CONCLUSIONS: In adults with T2D and ESKF undergoing hemodialysis, TBR was minimal and not influenced by rtCGM use. Compared with CBG testing, %TIR and %TAR improved during the rtCGM intervention. Future studies are needed to confirm the benefits of rtCGM in this population.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Galindo RJ, Moazzami B, Gerges A, et al. Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial. Diabetes Care. 2026. PMID: 42360278. doi:10.2337/dc26-0404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。